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Abstract: Polycystic ovary syndrome (PCOS) is a complex condition that involves metabolic,
psychological and reproductive complications. Insulin resistance underlies much of the
pathophysiology and symptomatology of the condition and contributes to long term complications
including cardiovascular disease and diabetes. Women with PCOS are at increased risk of obesity
which further compounds metabolic, reproductive and psychological risks. Lifestyle interventions
including diet, exercise and behavioural management have been shown to improve PCOS presentations
across the reproductive, metabolic and psychological spectrum and are recommended as first
line treatment for any presentation of PCOS in women with excess weight by the International
Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018.
However, there is a paucity of research on the implementation lifestyle management in women with
PCOS by healthcare providers. Limited existing evidence indicates lifestyle management is not
consistently provided and not meeting the needs of the patients. In this review, barriers and facilitators
to the implementation of evidence-based lifestyle management in reference to PCOS are discussed
in the context of a federally-funded health system. This review highlights the need for targeted
research on the knowledge and practice of PCOS healthcare providers to best inform implementation
strategies for the translation of the PCOS guidelines on lifestyle management in PCOS.
Keywords: weight management; exercise and physical activity; behaviour change; models of care;
healthcare professionals and systems
1. Introduction
Polycystic ovary syndrome (PCOS) is a complex condition involving reproductive, metabolic and
psychosocial components. The diagnosis of PCOS is based on criteria encompassing the common
presenting features of the condition; hyperandrogenism, oligo/ anovulation or menstrual disturbances
and polycystic ovaries [1]. Insulin resistance (IR) underpins many of the physical and biochemical
sequalae of PCOS [2–5]. Women with PCOS have higher body mass index (BMIs) than the general
population while a reduction in weight has been shown to improve insulin resistance and PCOS
symptoms [6–9]. The long term consequences of PCOS include cardiovascular disease (CVD), type II
diabetes mellitus (DM2), sleep apnoea, psychological complications and low self-esteem as well as
reproductive, fertility and pregnancy complications [10]. PCOS itself accounts for 19 to 28% of DM2 in
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reproductive aged women [11]. At the most recent estimate, PCOS was expected to cost the Australian
economy 400 million dollars conservatively [10]. Majority of this cost stems from expensive fertility
treatments and the long term chronic sequalae of IR and metabolic syndrome including DM2 and
CVD [12]. Lifestyle management including diet and exercise with or without concurrent behavioural
intervention has been shown to improve outcomes across the spectrum of the condition [9,13–18]. As a
result, the International Evidence-based Guideline for the Assessment and Management of Polycystic
Ovary Syndrome 2018 recommended healthy lifestyle behaviours for all women with PCOS regardless
of presenting symptoms [19].
Given the range of symptoms of PCOS, a number of disciplines may be involved in PCOS patient
care including general practice, allied health, and medical specialties. Lifestyle management has the
potential to improve symptoms managed by each of these disciplines, however evidence regarding
its implementation is lacking. In order to best provide care, barriers and facilitators to adequate and
comprehensive provision of evidence-based lifestyle management for PCOS by health professionals
must be understood.
2. Pathogenesis and Aetiology
The pathophysiology of PCOS is complex (Figure 1) with its aetiology remaining unclear. IR and
compensatory hyperinsulinemia are known to be key components of the syndrome, affecting 75% of
lean PCOS affected individuals and 95% of obese individuals [2,3]. The degree of insulin resistance
experienced by women with PCOS has also been shown to be above what would be expected given
their BMI [2,5]. Insulin resistance affects both hyperandrogenaemia and ovulation by acting on the
pituitary and ovaries arresting follicular development and increasing androgen production [20,21].
Insulin further inhibits the production of hepatic sex hormone binding globulin (SHBG) at the liver
contributing to the higher serum concentration of free androgens commonly seen in PCOS [22].
Decreasing IR through weight loss, lifestyle interventions or with insulin sensitising agents improves
the clinical features of PCOS while excess weight worsens IR and symptom severity [3,9,23,24].
Figure 1. A schema of the pathogenesis and aetiology of polycystic ovary syndrome (PCOS).
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3. Obesity and Polycystic Ovary Syndrome
It is well recognised that women with PCOS are more likely to be overweight or obese which
may reflect the impact weight has on symptom severity [25,26]. Obesity amongst women with PCOS
has risen with population increases in prevalence, from 51% to 74% in the years between 1987 and
2002 [27]. Obesity exacerbates many of the symptoms of PCOS including IR, hyperandrogenism and
menstrual disturbances [3,23,28]. Women with PCOS are more likely to be overweight, obese and
centrally obese compared to women without PCOS [29,30]. Teede et al. found women with PCOS gain
on average 2.6 kg more than their non-PCOS counterparts over a 10 year period [29]. Weight gain and
obesity contribute to negative emotional wellbeing and continues to be a key concern for women with
the condition [31,32].
A number of mechanisms may contribute to the higher rates of obesity and difficulty losing weight
in women with PCOS. Biological mechanisms such as altered metabolic flexibility, altered skeletal
muscle signalling and fat storage, brown adipose tissue thermogenesis and increased appetite have
been implicated while gut hormones responsible for regulating appetite such as cholecystokinin (CKK)
and ghrelin may also be dysregulated [4,33–40]. Behavioural differences between women with and
without PCOS may also explain the increased rate of obesity and weight reduction difficulties. Survey
evidence indicate these women’s daily diets tend to contain an additional 250 kJ compared to women
without PCOS [33]. Sedentary behaviour is also documented to be greater in women with PCOS than
the general public [33].
4. Management of Polycystic Ovary Syndrome
Management of PCOS utilises a diverse range of strategies due to the intersection of many
specialties managing the syndrome [41–43]. However, the International Evidence-based Guideline for
the Assessment and Management of Polycystic Ovary Syndrome 2018 endorse lifestyle modifications
as first-line treatment for all symptom presentations [19]. Lifestyle management programmes involve
a combination of dietary modifications, increased physical activity and behavioural adjustments to
achieve weight loss and/or maintenance [44].
5. Lifestyle Management
A summary of the various aspects of lifestyle management interventions and their benefits on
anthropometric, cardiovascular, metabolic, reproductive and psychological health, based on evidence
from meta-analyses, is shown in Table 1. The meta-analyses were identified using search terms
“lifestyle” or “diet” or “exercise” and “PCOS” using PubMed, Scopus and the Cochrane database of
systematic reviews, through expert referral and previous reviews with key publications selected for
their relevance by first authors.
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Table 1. A summary of current evidence from meta-analyses on lifestyle management in PCOS.
Author Intervention Type Control
Number of
Included
Papers
Total Number
of Participants
(n)
Population and
PCOS Diagnostic
Criteria
Key Findings
Moran et al. [9]
Structured dietary,
exercise or
behavioural
intervention or any
combination
Minimal
intervention
6 n = 164
PCOS (Rotterdam
or NIH)
Anthropometric: ↓weight, waist, WHR; NC BMI
Cardiovascular-Respiratory: NA
Metabolic: ↓OGTT insulin, FI; NC glucose, cholesterol
Reproductive: ↓ TT, hirsutism; NC FAI, SHBG
Psychological: NA
Domecq et al. [13]
Diet, physical exercise
or combination diet
and physical exercise
Metformin or
minimal
intervention
10 n = 610
PCOS
(criteria unspecified)
Lifestyle vs. Minimal intervention
Anthropometric: NA
Cardiovascular-Respiratory: NA
Metabolic: ↓ FBG, FBI, direct correlation between BMI
and FBG, no significant trend between BMI and FBG
Reproductive: ↓ FGS
Psychological: NA
Lifestyle vs. Metformin
Anthropometric: NA
Cardiovascular-Respiratory: NA
Metabolic: NSD FBG, FBI
Reproductive: NSD hirsutism score pregnancy rate
Psychological: NA
Haqq et al. [14]
Physical exercise
alone or combination
diet and
physical exercise
Usual care i.e.,
No active
intervention,
metformin,
untreated
controls,
placebo, healthy
diet only
7 n = 206
PCOS
(criteria unspecified)
Lifestyle Intervention (Combinatorial)
Anthropometric: NA
Cardiovascular-Respiratory: NA
Metabolic: NA
Reproductive:↑ FSH, SHBG; ↓ TT, androstenedione,
FAI, FGS; NSD LH
Psychological: NA
Exercise Alone
Anthropometric: NA
Cardiovascular-Respiratory: NA
Metabolic: NA
Reproductive:↑ FSH, SHBG, free testosterone; ↓ TT,
androstenedione, FGS; NSD LH, FAI, E2, LH:FSH
Psychological: NA
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Table 1. Cont.
Author Intervention Type Control
Number of
Included
Papers
Total Number
of Participants
(n)
Population and
PCOS Diagnostic
Criteria
Key Findings
Haqq et al. [15]
Physical exercise
alone or combination
diet and
physical exercise
Usual care
Sedentary
control, placebo,
diet only, or
metformin
12 n = 668
PCOS
(criteria unspecified)
Lifestyle intervention (Combinatorial)
Anthropometric: ↓ BMI, BM, WC, WHR, BF%
Cardiovascular-Respiratory: ↑ VO2 max
Metabolic: ↓ CRP; NSD insulin, glucose, IR, TG, TC,
LDL, HDL
Reproductive: NA
Psychological: NA
Exercise alone
Anthropometric: ↓ BMI, WC
Cardiovascular-Respiratory: ↓ RHR; ↑ VO2 max
Metabolic: NA
Reproductive: NA
Psychological: NA
Naderpoor et al. [16]
Lifestyle and
metformin or
metformin alone
Lifestyle or
lifestyle
and placebo
12 n = 608 PCOS (Rotterdam)
Lifestyle + Metformin vs. Lifestyle ± Placebo 6/12
Anthropometric: ↓ BMI, SAT; NSD WC, WHR, VAT
Cardiovascular-Respiratory: NSD SBP, DBP
Metabolic: NSD TC, HDL, LDL, TG, markers of IR, FBG
Reproductive: ↑menstrual frequency over 6/12 and
12/12; NC acne, FG score, FAI, SHBG, DHEAS, LH
Psychological: NSD QOL
Lifestyle±Placebo vs. Metformin
Anthropometric: NSD BMI; ↓WC
Cardiovascular-Respiratory: NA
Metabolic: NSD FBG, insulin AUC, glucose AUC
Reproductive: ↑ SHBG, TT; NSD FAI, menstrual cycles
6 to 12/12
Psychological: NA
Benham et al. [17]
Aerobic exercise,
resistance training,
combination of
aerobic and resistance
training both with
and without
behavioural and
diet interventions
Diet
intervention
alone or
standard care
14 n = 617
PCOS (Rotterdam
NIH, NIH
Phenotypes,
physician diagnosed
and unreported)
Meta-analysis
Anthropometric: ↓WC; NC BMI, BF%
Cardiovascular-Respiratory: ↓ SBP; NC VO2 max, DBP
Metabolic: ↓ FI, TC, LDL, TGs; ↑ HDL; NC FBG
Semi-quantitative Analysis
Reproductive: NC/↑ pregnancy ↑ovulation rate/cycles,
menstrual frequency/regularity menstrual cycle length
Psychological: NA
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Table 1. Cont.
Author Intervention Type Control
Number of
Included
Papers
Total Number
of Participants
(n)
Population and
PCOS Diagnostic
Criteria
Key Findings
Kite et al. [18]
Exercise or Control or
diet alone
18 n = 758
PCOS (Rotterdam
NIH,
physician diagnosed)
Exercise vs. Control—Change from Baseline
Anthropometric: NSD BMI, WHR, ↓WC, FM, FFM,
BF%
Cardiovascular-Respiratory: NSD SBP, DBP, VO2 max,
RHR
Exercise and diet Control or
diet alone
Metabolic: NSD FBG; ↓ FI, HOMA-IR, TC, LDL, TG;
NC HDL
Reproductive: NSD TT, SHBG, FT, FAI, FGS, E2,
DHEA-S, LH, FSH, LH:FSH ratio, PG, Prolactin, AMH,
Adiponectin.
Psychological: NA
AMH: anti-mullerian hormone; BF%: body fat %; BMI: body mass index; Corr(X,Y): direct correlation between X and Y; CRP: C-reactive protein; DBP: diastolic blood pressure; DHEAS:
dehydroepiandrosterone sulfate; E2: oestradiol; FAI: free androgen index; FBG: fasting blood glucose; FI: fasting blood insulin; FFM: fat free mass; FGS: ferriman-gallwey score; FM: fat
mass; FSH: follicle-stimulating hormone; FT: free testosterone; HDL: high density lipoprotein; HOMA-IR: homeostatic model of assessment-IR; IR: insulin resistance; LDL: low density
lipoprotein; LH: luteinising hormone; NC: no change; NSD: no significant difference; OGTT: oral glucose tolerance test; PG: progesterone; QOL: quality of life; RHR: resting heart rate; SAT:
subcutaneous adipose tissue; SBP: systolic blood pressure; SHBG: sex hormone binding globulin; TC: total cholesterol TG: triglycerides; TT: total testosterone; VAT visceral adipose tissue;
VO2 max: maximal oxygen consumption; WC: waist circumference; WHR: waist-to-hip ratio; NIH: National Institute of Health; NA: not assessed.
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6. Weight Management
Weight management is prioritised by health professionals and patients with PCOS. Qualitative
evidence published by Love et al. reported weight management was sought by PCOS women who had
concerns about their general health, fertility and appearance [45]. For overweight women with PCOS,
lowering body mass by 5% can reduce serum insulin and testosterone levels, and improve menstrual
and reproductive function [46–48]. Weight loss also improves depression and PCOS-specific quality of
life scores [49]. Thus, effective weight loss strategies are the focus of research. Lifestyle interventions
are capable of managing these immediate health concerns, as well as preventing long term chronic
diseases. Lifestyle interventions for prevention of chronic disease in other high risk populations have
been shown to be cost-effective, as associated costs are offset by reductions in non-intervention related
medical care [50].
Long term weight management does present challenges. In the general population, weight is
poorly maintained with few sustaining long-term weight loss [51,52]. Complex social, contextual,
cognitive and emotional obstacles challenge the maintenance of weight loss [53]. Women with PCOS
have greater drop-out rates in lifestyle intervention studies [54,55]. However high attrition in lifestyle
intervention studies are not uncommon for females and younger participants [56]. Psychological factors
contributing to poor trial adherence such as disordered eating, anxiety and depression could explain
difficulties these women experience maintaining weight [57]. Life stage-specific factors and priorities
have been barriers for younger participants adhering to lifestyle interventions [58,59]. For women
with PCOS who have excess weight, there are additional barriers to overcome that are not observed in
women without PCOS. These include a perception of lower self-worth which is related to the impact of
the condition on physical appearance [45]. Hyperandrogenemia and menstrual abnormalities; common
features in PCOS were found by Lim et al. to be associated with increased cravings for high fat and
fast foods. Psychological distress, another common comorbidity in women with PCOS, was associated
with cravings for sweet and high fat foods [60]. These cravings may reduce the likelihood of long-term
weight maintenance.
7. Diet Intervention
The International Evidence-based Guideline for the Assessment and Management of Polycystic
Ovary Syndrome 2018 recommend that a variety of dietary approaches should be utilised to reduce
dietary energy intake, while incorporating general healthy eating principles [19]. Dietary management
has been used alone and in combination with exercise and behavioural therapy for weight loss and
management in PCOS [8,48,61,62]. To achieve weight loss through diet modification in women with
PCOS, there should be a negative energy balance of approximately 30% to achieve an energy deficit of
500–750 kcal per day [19]. These recommendations are consistent with general population guidelines
that suggest low-calorie diets containing sufficient carbohydrates and proteins with low-fat intake will
provide optimum results [63]. Diet advice provided to women with PCOS often specifies a reduction
in dietary glycaemic index in addition to overall calorie reduction to induce weight loss [64].
All diets that aim to reduce weight are considered beneficial [19]. The absence of prescribed
dietary interventions serves as an opportunity for healthcare providers to tailor dietary modifications
towards the patient’s individual needs and preferences as no diet is known to be conclusively more
effective in PCOS [65].
8. Physical Activity
Physical activity (any bodily movement produced by skeletal muscles that requires energy expenditure)
and exercise (activity requiring physical effort, carried out to sustain or improve health and fitness) for
all women with PCOS has been shown to improve presentations of PCOS both through weight loss
and independently of weight loss [66–68]. To prevent weight gain and maintain health, International
Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018
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recommend that different durations and intensities of exercise are to be met for different age groups [19,69].
These recommendations are in accordance with those for the general population. Adults aged 18–64
should perform physical activity for a minimum of 150 min per week of moderate intensity, 75 min
per week of vigorous intensity or an equivalent of both [19,69]. Recommendations for adults include
muscle-strengthening activity on two non-consecutive days [19,69]. For adolescents, the recommendations
for physical activity are more intensive, recommending a minimum of 60 min per day most days of the
week [19,69]. The physical activity should be moderate to vigorous intensity and complemented with
muscle-strengthening activities performed at least three times per week [19,69]. In general, minimised
sedentary, screen and sitting time are advised [19,69]. Regular exercise or physical activity is considered
important for women with PCOS, but evidence from the general population suggests exercise conjunction
with a hypocaloric diet has a greater ability to increase weight loss [70].
9. Behavioural Intervention
The International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary
Syndrome 2018 recommend the inclusion of behavioural strategies in lifestyle interventions to optimise weight
management, improve general health and maintain emotional wellbeing in PCOS women [19]. Behavioural
therapy aims to modify lifestyle behaviours and involves implementing goal setting, self-monitoring,
identifying barriers and problem solving [57,71]. These strategies are used in conjunction with diet
modification and exercise therapy to increase program adherence and efficacy [72]. These are often provided
by a health professional such as a psychologist [71]. When ongoing contact with health professionals is
combined with social support, behavioural therapy is often associated with stronger positive outcomes in
the general population [73]. Adolescents with PCOS provided with nutrition counselling and behavioural
therapy experienced greater weight loss compared to those receiving neither however the precise nature of
the intervention was not reported [61]. Given their efficacy in the general population they are also likely to
result in beneficial outcomes for women with PCOS.
10. The Role of Healthcare Professionals in Lifestyle Management in Polycystic Ovary Syndrome
A number of different medical and allied health practitioners are likely to be involved in PCOS care
across different life stages, including general practitioners, allied health professionals and specialists
such as obstetrician and gynaecologists and endocrinologists [74]. Weight and lifestyle management
are beneficial across all health professional symptom domains thus each role represents an opportunity
to engage in lifestyle management.
However, it should be noted women with PCOS have reported dissatisfaction with provision of
care and support from physicians when compared to women without PCOS [32,75]. A 2018 study
concluded that women with PCOS report overall greater distrust in the opinions of their primary
care physicians and reportedly had more arguments with other healthcare professionals, compared
to women without PCOS [75]. This may impact the ability of PCOS care providers to effectively
implement lifestyle management.
11. General Practitioners
General practitioners (GPs) are responsible for the initial diagnosis, treatment of less complex issues
and overseeing continuity of care in chronic diseases [76]. In PCOS, provision of evidence-based resources,
lifestyle intervention and psychological health should be effectively managed in primary care [77].
The role of the GP as the coordinator of patient care means that they are more likely to have
regular contact and ongoing relationships with patients compared with other medical specialties and
allied health professionals. This places GPs in an ideal position to facilitate long term lifestyle and
weight management. The role of the GP in primary care allows discretionary prescription of lifestyle
management themselves, or referral to the appropriate medical or allied health specialist if it is beyond
their expertise. However, evidence suggests GPs do not regularly engage in lifestyle management.
One Australian survey identified less than one third of overweight and obese patients reported their
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GP mentioning lifestyle management in the preceding twelve months [78]. Patients also do not appear
to have confidence that GPs will be able to manage their weight effectively [79]. However, these
were derived from the general population and we do not have information specific to the lifestyle
management of PCOS.
12. Allied Health
Allied health professionals are essential in the collaborative management of complex and chronic
conditions such as PCOS [76]. Each allied health professional can provide their own expertise
on management of PCOS as part of multidisciplinary care that is prioritised by the International
Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
2018 [19]. Lifestyle management can be outsourced by other medical professionals to allied health
professionals to support the intensive and complex lifestyle and weight management interventions [19].
Allied health professionals involved in PCOS care often include, but are not limited to, dieticians,
exercise physiologists, physiotherapists and psychologists [19,69].
When allied health are utilised in a multidisciplinary PCOS setting, participants appear to have
better weight loss results. Geier et al. found that nearly 70% of adolescents with PCOS demonstrated
weight loss or maintenance when supported by a health psychologist and dietitian as part of a
multidisciplinary team however as discussed earlier this intervention was not well described [61].
Dieticians and exercise physiologists can educate and recommend a patient-specific diet and exercise
plan tailored for weight loss or prevention of weight gain [64,80]. Allied health services appear
underutilised in the management of PCOS in many countries [64]. A 2005 survey of UK dietitians
and women with PCOS by Jeanes et al. reported that although most women were following a diet,
less than 15% had consulted a dietitian, and a major component of diet advice was collected from less
reputable sources including books and the internet [64].
Psychologists could also be involved in the management of the psychological and psychosocial
concerns common in women with PCOS [19]. Trained psychologists could also deliver behavioural
support in lifestyle modification, although the extent to which psychologists engage with lifestyle
management in PCOS is not known.
13. Obstetricians-Gynaecologists
The role of obstetricians-gynaecologists (OBGYNs) in PCOS predominantly concerns the
management of menstrual irregularities and infertility. Although a majority of OBGYNs
consider lifestyle advice as first line management for non-fertility reasons in women with PCOS,
the proportion considering this management as first line is lower than the proportion that do in other
specialities [42,43,81]. Greater provision of healthy lifestyle advice is needed as the International
Evidence-based Guideline for Assessment and Management of Polycystic Ovary Syndrome 2018
recommends that healthy lifestyle advice to be recommended to all patients with PCOS, regardless of
other presentations [19].
14. Endocrinologists
Endocrinologists form an integral part of the PCOS care team over a lifetime given that PCOS
is an endocrinopathy (Figure 1) with inherent risks of obesity, metabolic syndrome, CVD, IR, DM2
and dyslipidaemia. Past studies have consistently shown endocrinologists are more likely to discuss
lifestyle management for both fertility and non-fertility reasons when compared to their OBGYN
counterparts [42,43,81]. However, lifestyle advice is often deemed to be unsatisfactory or general
and inadequate by patients [82,83]. Advice may only be provided to women who appear overweight
meaning health professionals are missing opportunities to prevent weight gain [82]. This is of particular
importance given women with PCOS gain more than their reproductive aged peers, a population
group already predisposed to significant longitudinal gains [29,84].
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15. Barriers and Facilitators for Evidence Based Lifestyle Management
Despite evidence supporting lifestyle management in PCOS and endorsement by the International
Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018 there
exist a number of barriers to the implementation of evidence-based lifestyle management at both the
systemic and individual practitioner level. The barriers discussed below are mostly within the context of
federally-funded healthcare systems as exists in Australia. The studies included in this review have been
conducted in a number of developed countries including the USA, Australia, Ireland, the Netherlands,
Portugal and Singapore, where referral pathways and funding structures likely differ. Despite the differences
in healthcare systems, there appears to be common barriers to lifestyle management across these countries,
highlighting clinical knowledge gaps on the implementation of lifestyle management within healthcare
systems in developed countries. It is even more concerning when no published data exists for developing
nations grappling with the similar issues for women with PCOS.
In general, many PCOS patients report disappointment with information provided to them about
lifestyle management [32,83,85]. Furthermore, the “silo-ed” nature of a medical system fragmented
by specialty has been blamed for some of the discontent among women with PCOS [74,86]. Lack of
communication between health professionals results in delays to diagnosis and treatment, insufficient
use of allied health and inadequate information provision exacerbating dissatisfaction in this patient
population [32,83,85].
The barriers to the implementation of effective lifestyle management are not known indicating
the need for targeted research among PCOS healthcare providers. Much of the literature focuses
on barriers and facilitators of lifestyle intervention experienced by GPs which is consistent with the
perception that lifestyle management is the responsibility of the GP [77]. In the wider population
systemic barriers such as time pressure and insufficient financial reimbursement are commonly cited
barriers to the provision of lifestyle and obesity management in primary care [87–94]]. Lack of clarity
in healthcare roles appears to be an issue for coordination of lifestyle management between other
healthcare providers [93]. In PCOS others have also implicated long waiting times for allied health
providers as catalysts for patient’s accessing alternative sources of health information including
potentially unreliable information on the internet and in books [32]. Clinicians’ perception of patient
access to and the availabilty of allied health professionals has impacted on their decision to discuss
lifestyle management in the general population [88,95,96]. GPs were unlikely to refer patients to allied
health professionals to support lifestyle management if they perceived that the consultations were
expensive, the provider was located too far away and/or inaccessible by public transport [95,96].
Ko et al. when assessing barriers to lifestyle management in a multidisciplinary PCOS setting
identified other systemic barriers to lifestyle management implementation in PCOS. These included
short consultations, non-standardised delivery of lifestyle management, lack of enforcement and follow
up of interventions and unsatisfactory coordination with allied health staff [97]. Further, the absence of
culturally appropriate resources meant when advice was provided it was not as effective for some
patient groups [97]. This study was part of a quality improvement framework for a PCOS fertility
clinic in Singapore and the barriers reported may not be easily translated to other settings.
General pratcitioners are often held in high esteem by patients which provides them great influence
and opportunity to reinforce health messages [92]. Yet, past surveys of healthcare professionals have
described how health professionals, find it difficult to provide guidance on lifestyle management
due to perceived lack of expertise and training [87,88,91–93]. GPs are less inclined to engage
in lifestyle management if they percieve a lack of motivation and responsibility for health in
their patients [87,89–93,95,96,98,99]. Some healthcare professionals report a lack of motivation
to implement lifestyle management as poor patient compliance means repeated messages made
during lifestyle consultations are unlikely to prompt changes [88,89,93,98]. In both PCOS and the
general population, practitioners have reported patients themselves lack the time and priority for
lifestyle interventions [97,98]. These patients were more likely to desire or be offered pharmaceutical
treatments [97,98].
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Fear of deterioration of patient relationship and offending patients makes it difficult for clinicians
to initiate lifestyle consultations as discussing sensitive topics like weight management can be
considered judgemental [92,93,99]. The provider-patient partnership can also be strained by clinicians’
own experiences and expectations regarding lifestyle management [93,95]. A study by Kim et al.
reported high expectiations may often result in clinicians pushing patients too hard for desired results
and deteriorating the vital patient-provider partnership [95]. Although patients’ own unrealistic
expectations make lifestyle management difficult to implement [89]. Women with PCOS have detailed
a perceived lack of empathy from doctors in discussions of weight and some clinicians admitted they
found it difficult to empathise thus supporting lifestyle management is difficult [32,93].
A summary of common barriers cited in studies assessing clinician attitudes to obesity and weight
management are provided in Table 2. These are not PCOS-specific and are unlikely to reflect the unique
issues experienced by clinicians managing women with the condition. Further barriers specific to
the implementation of lifestyle management in a PCOS context need to be better understood to best
address these issues.
Table 2. A summary of key barriers to implementation of lifestyle interventions experienced by
healthcare professionals at the level of the health system and the individual.
Barriers to Lifestyle and
Obesity Interventions
Studies with Identified
Barrier(s) Potential Facilitators and Solutions
Health System Level
Lack of time
Kushner et al. [88]
Campbell et al. [89]
Nicholas et al. [87]
Jansink et al. [93]
Lambe et al. [92]
Passey et al. [94]
Salinas et al. [91]
Epling et al. [90]
• Greater team effort between clinicians, patients
and policy makers to propose efficient and
necessary time of consultations [88]
• Modifications made to fee-for-service systems to
increase the reward for lifestyle counselling [87]
Lack of reimbursement
Kushner et al. [88]
Passey et al. [94]
Lambe et al. [92]
Salinas et al. [91]
Epling et al. [90]
Ko et al. [97]
• Ensure that amount of reimbursement available
for lifestyle management reflects government
health policy expectations [97]
Limited access to and
availability of allied
health providers and
other members of the
multidisciplinary
care team
Nicholas et al. [87]
Passey et al. [94]
Epling et al. [90]
Teixeira et al. [98]
Glauser et al. [99]
Kim et al. [95]
• Recognition that multi-disciplinary facilities and
schemes should be available for obese people
with and without existing chronic diseases [79]
• Greater communication along clinician referral
pathways as it is likely that there are higher
referral rates (to co-located providers) when trust
between providers is established [95]
Provider location Kushner et al. [88]Kim et al. [95]
• Increase service availability as health providers
report being more likely to refer where services
are readily available [95]
Lack of coordination
between healthcare
providers
Jansink et al. [93]
Kim et al. [95]
• Greater communication between providers
to ensure individual roles are clear and
management is effective [93]
Lack of high quality and
affordable material for
patient education
Jansink et al. [93]
Kushner et al. [88]
• More research into the efficacy of pamphlets and
newsletters [88]
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Table 2. Cont.
Barriers to Lifestyle and
Obesity Interventions
Studies with Identified
Barrier(s) Potential Facilitators and Solutions
Health Professional Level
Self-perceived lack of
expertise and training
Kushner et al. [88]
Nicholas et al. [87]
Ampt et al. [96]
Jansink et al. [93]
Lambe et al. [92]
Salinas et al. [91]
Glauser et al. [99]
• Updated training and continued professional
development with increased focus on
implementing concepts of lifestyle interventions
into practice [88]
Perception of low patient
motivation,
responsibility, and/or
compliance
Kushner et al. [88]
Campbell et al. [90]
Nicholas et al. [87]
Ampt et al. [96]
Lambe et al. [92]
Jansink et al. [93]
Salinas et al. [91]
Epling et al. [90]
Glauser et al. [99]
Kim et al. [95]
Teixeira et al. [98]
Ko et al. [97]
• Patients are more likely to adhere to advice if
they can recall it. Pertinent information needs to
be delivered clearly and concisely [88]
• Lifestyle interventions need to be tailored to meet
patient’s skill capacity, accessibility to facilities
and with support for possible psychosocial
barriers [93]
• Implementation of patient centred motivational
interviewing [93]
Poor patient-provider
partnership Jansink et al. [93]
• Combatting false or high expectations of health
providers to prevent resistance from patient [93]
Reluctance to or fear of
offending patient
Jansink et al. [93]
Lambe et al. [92]
Glauser et al. [99]
• Training in effective communication, particularly
when involving sensitive issues such as
weight [79]
Motivation to implement
based on provider’s own
interests, expectations
and experiences
Jansink et al. [93]
Kim et al. [95]
Teixeira et al. [98]
• Improved education and feedback to clinicians
about interventions to negate personal
opinions [95]
Limited patient time and
priority to regularly
attend consultations
Teixeira et al. [98]
Ko et al. [97]
• Utilisation of information technology-enabled
lifestyle management tools [97]
• Increase opportunities for incidental activity [97]
16. Knowledge and Practice Gaps
This review has identified a number of knowledge gaps within the available literature implicating
a strong need for further research. Only one study reported PCOS-specific barriers, while only two
reported on barriers experienced by specialists. Thus, whether the barriers discussed in this review
apply outside of general population primary care remains purely speculative. Barriers and facilitators
have been discussed in the context of a federally-funded healthcare system such as exists in Australia
and thus the recommendations from this review will not be uniformly relevant for all international
contexts. Future research should aim to identify which women with PCOS are receiving lifestyle
advice and if this advice conforms to recommendations made by the International Evidence-based
Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018. Furthermore,
there needs be greater insight into the type of advice and support women with PCOS would appreciate
to facilitate their adherence to lifestyle interventions. Knowing how to best support health professionals
in providing this advice is also vital, thus barriers and facilitators to the implementation of lifestyle
management for PCOS need to be identified.
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17. Conclusions
While the benefits of lifestyle interventions in women with PCOS have been established and
endorsed by the International Evidence-based Guideline for the Assessment and Management of
PCOS 2018, this review highlights the potential barriers to its the implementation and translation into
clinical practice. The extent to which providers are prescribing lifestyle management for PCOS is not
well described. Whether the provision of lifestyle management is according to evidence is not known.
Furthermore, barriers to the implementation of these lifestyle recommendations for women with
PCOS that are faced by various health professionals has not been explored outside of one Singaporean
study. Further research should seek to address these unknowns to facilitate translation of guideline
recommendations for lifestyle management into clinical practice and thus better outcomes for women.
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